Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752740/
https://www.ncbi.nlm.nih.gov/pubmed/26877767
http://dx.doi.org/10.1186/s13069-016-0038-0
_version_ 1782415780801937408
author Shi, Sen
Koya, Daisuke
Kanasaki, Keizo
author_facet Shi, Sen
Koya, Daisuke
Kanasaki, Keizo
author_sort Shi, Sen
collection PubMed
description Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors.
format Online
Article
Text
id pubmed-4752740
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47527402016-02-14 Dipeptidyl peptidase-4 and kidney fibrosis in diabetes Shi, Sen Koya, Daisuke Kanasaki, Keizo Fibrogenesis Tissue Repair Review Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors. BioMed Central 2016-02-13 /pmc/articles/PMC4752740/ /pubmed/26877767 http://dx.doi.org/10.1186/s13069-016-0038-0 Text en © Shi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Shi, Sen
Koya, Daisuke
Kanasaki, Keizo
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title_full Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title_fullStr Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title_full_unstemmed Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title_short Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
title_sort dipeptidyl peptidase-4 and kidney fibrosis in diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752740/
https://www.ncbi.nlm.nih.gov/pubmed/26877767
http://dx.doi.org/10.1186/s13069-016-0038-0
work_keys_str_mv AT shisen dipeptidylpeptidase4andkidneyfibrosisindiabetes
AT koyadaisuke dipeptidylpeptidase4andkidneyfibrosisindiabetes
AT kanasakikeizo dipeptidylpeptidase4andkidneyfibrosisindiabetes

Ejemplares similares